IKT · TickerCove

IKTInhibikase Therapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-16

Horizon

Issued 2026-09-16 at $2.31 · now $2.31 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, IKT has typically landed between $1.56 and $3.23 — a range of −32.3% to +39.9% from the issuance price $2.31.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.

Actual close
Typical path (median)
Middle 50% of outcomes
90% range

1,417 overlapping 1 month windows · 2020-12-23 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($2.31) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

52-week range$2.31 · 81% of range

$1.41 low$2.52 high

Trailing 52 weeks to 2026-09-16 — factual context, not a signal.

Base rate up · monthiClimatology base rate that a US-listed stock rises over a month, with its 90% CI and ≈1,408 effective observations. Not a call on this stock — we have no evidence its odds differ.

53.9%

90% CI 51.7%–56.1%

Distribution · month iiThe price-anchored range: typical move (median), and the p90 downside/upside — 90% of similar periods stayed inside these. Ranges, not a prediction of direction.

−4.0%

typical move · IQR 25.2%

−32.3%worst (p90)+39.9%best (p90)

Insider convictioniOpen-market common-stock purchases by company insiders in the last 90 days (grants and option exercises excluded). Historical tendency, not advice — detail below.

conviction buys

0 open-market sales

Congress disclosuresiRecent disclosed congressional trades for this company. Purchase clusters (≥2 members buying within 90 days) historically preceded a modestly higher forward return (+32 bp/mo in 2022–2026, +45 bp/mo in 2015–2021) — a descriptive tendency, not a forecast input. Detail below.

0 buys · 0 sells · 0 members

cluster tilt persisted, ~halved after 2021

Where IKT has typically landed a month from the 2026-09-16 close of $2.31 — the range is history, not a prediction.

now $2.31 (+0.0%)
typical $2.22 (-4.0%)
middle 50% $1.93–$2.51
90% range $1.56–$3.23

Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,417 windows spanning 2020-12-23 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.

Start	Return	Max drop	Max rise
3 worst
2023-09-06	−61.5%	−61.5%	+0.0%
2023-09-08	−59.9%	−59.9%	+4.0%
2023-09-11	−59.1%	−61.4%	+0.0%
3 best
2023-12-27	+176.7%	+0.0%	+176.7%
2023-12-28	+158.2%	+0.0%	+163.1%
2023-12-26	+140.7%	−5.7%	+140.7%

1,417 overlapping windows · 2020-12-23 – 2026-09-16 · not cherry-picked

Seasonality · by month i

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.

Jan

33%

+19.0%

n=6

Feb

67%

−1.6%

n=6

Mar

17%

−0.7%

n=6

Apr

33%

−11.9%

n=6

May

50%

+2.9%

n=6

Jun

17%

−16.7%

n=6

Jul

50%

−5.0%

n=6

Aug

67%

+2.7%

n=6

Sep

−12.2%

n=6

Oct

40%

+7.7%

n=5

Nov

80%

+0.7%

n=5

Dec

60%

+7.6%

n=5

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Date	Person	Role	Action	Shares @ price	Value	Ownership Δ	vs S&P 1m	vs S&P 6m	Owned after	Filing
2025-11-21	Sands Capital Life Sciences Pulse Fund II, L.P.	tenPercentOwner	Purchase	2,068,965 @ $1.45	$3.0M	+18.9% of holding	+2.0%	−0.4%	13,018,965	Form 4 · filed 3 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

93 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

Date	Person	Role	Action	Shares	Owned after	Filing
2026-07-30	BERMAN DENNIS N	director	Option exercise	21,854	21,854	Form 4
2026-07-30	BERMAN DENNIS N	director	Option exercise	21,854	0	Form 4
2026-07-29	RA CAPITAL MANAGEMENT, L.P.	director	Other acquisition	18,030,000	18,030,000	Form 4
2026-07-29	RA CAPITAL MANAGEMENT, L.P.	director	Other acquisition	18,030,000	6,970,000	Form 4
2026-07-29	RA CAPITAL MANAGEMENT, L.P.	director	Other acquisition	18,030,000	18,030,000	Form 4
2026-07-29	RA CAPITAL MANAGEMENT, L.P.	director	Other acquisition	18,030,000	6,970,000	Form 4
2026-07-29	RA CAPITAL MANAGEMENT, L.P.	director	Other acquisition	18,030,000	18,030,000	Form 4
2026-07-29	RA CAPITAL MANAGEMENT, L.P.	director	Other acquisition	18,030,000	6,970,000	Form 4
2026-07-29	RA CAPITAL MANAGEMENT, L.P.	director	Other acquisition	18,030,000	18,030,000	Form 4
2026-07-29	RA CAPITAL MANAGEMENT, L.P.	director	Other acquisition	18,030,000	6,970,000	Form 4
2026-07-29	RA CAPITAL MANAGEMENT, L.P.	director	Other acquisition	18,030,000	18,030,000	Form 4
2026-07-29	RA CAPITAL MANAGEMENT, L.P.	director	Other acquisition	18,030,000	6,970,000	Form 4
2026-06-26	Aurentz Vincent	director	Award / grant	155,000	155,000	Form 4
2026-06-26	BERMAN DENNIS N	director	Award / grant	155,000	155,000	Form 4
2026-06-26	Bellini Roberto	director	Award / grant	155,000	155,000	Form 4
2026-06-26	Canner David	director	Award / grant	155,000	155,000	Form 4
2026-06-26	Munshi Amit	director	Award / grant	155,000	155,000	Form 4
2026-06-26	Kush Arvind	director	Award / grant	155,000	155,000	Form 4
2026-02-21	Munshi Amit	director	Disposition	19,089	38,176	Form 4
2026-02-21	Aurentz Vincent	director	Disposition	255,299	510,596	Form 4
2026-02-21	Cabell Christopher	officer	Disposition	338,282	676,564	Form 4
2026-01-05	Cabell Christopher	officer	Award / grant	900,117	900,117	Form 4
2026-01-05	McIntyre David	officer	Award / grant	986,319	986,319	Form 4
2026-01-05	Iwicki Mark T	director	Award / grant	4,982,706	4,982,706	Form 4
2025-06-30	Canner David	director	Award / grant	108,176	108,176	Form 4
2025-06-30	BERMAN DENNIS N	director	Award / grant	108,176	108,176	Form 4
2025-06-30	Kush Arvind	director	Award / grant	108,176	108,176	Form 4
2025-06-30	Aurentz Vincent	director	Award / grant	108,176	108,176	Form 4
2025-06-30	Bellini Roberto	director	Award / grant	108,176	108,176	Form 4
2025-06-30	Munshi Amit	director	Award / grant	108,176	108,176	Form 4
2025-04-14	McIntyre David	officer	Award / grant	1,775,539	1,775,539	Form 4
2025-02-21	Iwicki Mark T	director	Award / grant	602,346	602,346	Form 4
2025-02-21	Aurentz Vincent	director	Award / grant	134,427	134,427	Form 4
2025-02-21	Cabell Christopher	officer	Award / grant	1,100,705	1,100,705	Form 4
2025-02-21	Munshi Amit	director	Award / grant	57,265	57,265	Form 4
2025-02-17	Iwicki Mark T	director	Award / grant	1,794,291	1,794,291	Form 4
2025-02-14	BERMAN DENNIS N	director	Award / grant	39,620	39,620	Form 4
2025-02-14	Canner David	director	Award / grant	116,585	116,585	Form 4
2025-02-14	Canner David	director	Award / grant	22,640	22,640	Form 4
2025-02-14	Munshi Amit	director	Award / grant	56,600	56,600	Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Resolves in i

28d remaining

2026-09-173% elapsed2026-10-15

Logged immutably 2026-09-17; scored automatically on 2026-10-15 — no edits, ever.

Earnings & context analysis

These panels are being prepared. They are generated by multiple language models, checked, and stored before display — never written live for a page view. Until a model panel has been generated and reviewed for a company, nothing is shown here, honestly, rather than a placeholder.

Calibration i

Every forecast is logged when made and scored when the month is up. The record is shown from the day it starts — young and honest.

How scoring works →

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

Reported insider & political trades

Congressional disclosures

Seasonality · by month i